Showing 4021-4030 of 5957 results for "".
- Lumibird Launches C.DIAG Dry Eye Diagnostic Aid Platformhttps://modernod.com/news/lumibird-launches-cdiag-dry-eye-diagnostic-aid-platform-platform/2482260/Lumibird Medical announced the launch of the C.DIAG, a new-generation dry eye diagnostic aid platform with integrated AI algorithms. This new component of the C.SUITE is designed to enable healthcare professionals to diagnose, treat and educate dry eye patients. &ldq
- Heidelberg Engineering to Showcase New Imaging Technology at ARVOhttps://modernod.com/news/heidelberg-engineering-to-showcase-new-imaging-technology-at-arvo/2482254/At the upcoming ARVO meeting in Seattle, Heidelberg Engineering will showcase a wide range of imaging applications from basic vision research to clinical trials and guided therapy. SeeLuma For the first time, Heidelberg Engineering will demonstrate
- Qlaris Bio Completes $24 Million Series B Financing Round to Advance IOP-lowering Drug Candidate for Glaucomahttps://modernod.com/news/qlaris-bio-completes-24-million-series-b-financing-round-to-advance-iop-lowering-drug-candidate-for-glaucoma/2482252/Qlaris Bio announced it has closed a $24 million Series B financing round to support the continued clinical development of QLS‑111, a first-in-class therapeutic being developed to lower IOP by targeting episcleral venous pressure (EVP). Qlaris is currently conducting two US ph
- Iantrek Presents New Data for CycloPen System with AlloFlo Carriershttps://modernod.com/news/iantrek-presents-new-data-for-cyclopen-system-with-alloflo-carriers/2482249/At the ASCRS meeting in Boston, Iantrek presented new data for its micro-interventional glaucoma surgical device CycloPen with AlloFlo. CycloPen is Iantrek’s microinterventional system for the ab-interno construction, modification, reinforcement and repair of a cyclodialysis.
- Inflammasome Therapeutics Announces First Patient Dosed in Geographic Atrophy Clinical Trialhttps://modernod.com/news/inflammasome-therapeutics-announces-first-patient-dosed-in-geographic-atrophy-clinical-trial/2482248/Inflammasome Therapeutics announced the first patient has been dosed in a first-in-class clinical trial for a sustained release implant for geographic atrophy (GA) due to age-related macular degeneration (AMD). The phase 1 trial (ClinicalTrials.gov ID NCT06164587) is sponsored by the Univers
- Aldeyra Therapeutics Announces Planned Pivotal Clinical Trial for RP Drug Candidatehttps://modernod.com/news/aldeyra-therapeutics-announces-planned-pivotal-clinical-trial-for-retinitis-pigmentosa-drug-candidate/2482247/Aldeyra Therapeutics hosted the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City on April 25 where it presented recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the treatment of retinitis pigmentosa.
- RevOpsis Secures $16.5 Million Seed Funding to Advance First-in-Class Tri-Specific Therapy for Wet AMD Treatmenthttps://modernod.com/news/revopsis-secures-165-million-seed-funding-to-advance-first-in-class-tri-specific-therapy-for-wet-amd-treatment/2482246/RevOpsis Therapeutics announced it has successfully closed its first seed funding round, raising $16.5 million to develop and commercialize treatments for chronic multifactorial diseases through the company's fully human multispecific proprietary Rev-Mod Platform. The 
- DigitalOptometrics Surpasses 2 Million Remote Eye Examshttps://modernod.com/news/digitaloptometrics-surpasses-2-million-remote-eye-exams/2482242/DigitalOptometrics announced it has surpassed 2 million remote comprehensive eye exams. DigitalOptometrics' remote eye exam platform is designed to allow optometrists to conduct comprehensive eye exams remotely, integrating video conferencing with remote operation of opht
- Ocugen Completes Dosing in Phase 1/2 Trial of OCU410 for Geographic Atrophyhttps://modernod.com/news/ocugen-advances-armada-trial-of-ocu410-to-treat-patients-with-geographic-atrophy/2482238/Ocugen announced dosing is complete in the second cohort of its phase 1/2 ArMaDa trial of OCU410, an adeno-associated viral vector 5 human RORA (AAV5-hRORA) gene therapy being developed for geographic atrophy (GA). Up to 13
- EyeSouth Partners Affiliates With Community Eye Care Specialists in New Yorkhttps://modernod.com/news/eyesouth-partners-affiliates-with-community-eye-care-specialists-in-new-york/2482233/EyeSouth Partners announced it has partnered with Community Eye Care Specialists, representing its first affiliation in New York, third affiliation in Pennsylvania. and 40th affiliation overall. Financial terms of the deal were not disclosed. EyeSouth is an eye care-focused ma